Precigen’s PAPZIMEOS Quarterly Revenue Rises 37% to $72.9 Million
Key Facts
Precigen said on November 4 that net revenue from PAPZIMEOS was $72.9 million in the third quarter of 2026, up 37% from the previous quarter, as the company reported net income and positive operating cash flow. Total revenue was $74.1 million, compared with an annual increase of $71.2 million from the third quarter of 2025. The company attributed the increase mainly to recording commercial sales of PAPZIMEOS following the U.S. Food and Drug Administration’s approval of the treatment in August 2025. The results show the product has become a key driver of the company’s revenue since commercial sales began. Cumulative net revenue from the product since launch reached $151 million as of the earnings announcement.
PAPZIMEOS revenue growth accelerated quarter over quarter after net revenue of $53.1 million in the second quarter of 2026, more than double the previous quarter’s revenue. In the third quarter, the figure rose to $72.9 million, the filing said, reflecting continued sales expansion during the period. The filing did not provide a comparison between actual sales and market expectations. The company said total revenue increased $71.2 million year over year, attributing the increase mainly to the start of recorded commercial sales of the drug. The U.S. approval in August 2025 preceded this shift in revenue.
Precigen reported net income of $35.8 million in the third quarter, or $0.08 per diluted share. That compared with a net loss attributable to common stockholders of $325.3 million in the same period a year earlier. The comparison shows a significant shift in the bottom line between the periods, while the information available here did not specify how much PAPZIMEOS or other items contributed to the change. On operating liquidity, net cash generated from operating activities was $11.9 million during the quarter. The chief financial officer said the company achieved positive cash flow “a full quarter ahead of that guidance.”
Cash, cash equivalents and investments totaled $51.0 million on September 30, 2026. The figure puts reported quarter-end liquidity alongside the positive operating cash flow recorded during the period, without by itself determining the company’s future spending or financing path. On treatment use, Precigen said more than 500 patients had started PAPZIMEOS and more than 300 had completed treatment as of the November 4 earnings announcement. These figures indicate an expanding patient base since launch, alongside growth in commercial revenue. The company’s available data did not provide an independent estimate of market size or future sales.
On clinical data, Precigen said long-term follow-up data presented at the 2026 AAO-HNSF meeting showed complete responses continuing for up to five years after treatment. In its assessment, the Food and Drug Administration had recorded complete response rates of 51% after 12 months and 43% after 24 months, and described the benefit as clinically meaningful. These results provide clinical context for the product, while the patient and revenue figures reflect its commercial use since launch. In the market, Precigen shares, trading under the ticker PGEN, closed at $4.29 on November 17, 2026. B. Riley maintained its “Buy” rating on November 16, while cutting its price target to $11 from $12.
The next regulatory milestone is in Europe: Precigen said the European Medicines Agency is reviewing a marketing authorization application for zopapogene imadenovec, submitted in November 2025 to treat adults with recurrent respiratory papillomatosis. The filing did not specify when the agency is expected to make a decision. The company also said in an earlier update that an open-label study assessing the efficacy of repeat dosing in adults with the disease was enrolling patients. The European review and ongoing study provide context for the treatment’s development beyond current sales. In its latest filing, the company said the European application was under review.